| scholarly article | Q13442814 |
| P50 | author | Peng Yue | Q90468319 |
| Taylor Harper | Q90468322 | ||
| Silvia M Bacot | Q90468326 | ||
| Monica Chowdhury | Q90468327 | ||
| Shiowjen Lee | Q90468330 | ||
| Adovi Akue | Q90468333 | ||
| Mark A Kukuruga | Q90468336 | ||
| Tao Wang | Q90468340 | ||
| Gerald M Feldman | Q90468344 | ||
| P2860 | cites work | CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms | Q24534904 |
| Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 | ||
| Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 | ||
| Modeling T cell antigen discrimination based on feedback control of digital ERK responses | Q24814731 | ||
| Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines | Q26772715 | ||
| Overcoming T cell exhaustion in infection and cancer | Q26829885 | ||
| Nivolumab plus ipilimumab in advanced melanoma | Q27852310 | ||
| Inhibition of Mutated, Activated BRAF in Metastatic Melanoma | Q27860458 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Hepatotoxicity with combination of vemurafenib and ipilimumab | Q28288255 | ||
| Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial | Q29614756 | ||
| Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer | Q29620902 | ||
| Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma | Q30890582 | ||
| Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade | Q33898182 | ||
| In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates | Q34421845 | ||
| ERK implication in cell cycle regulation | Q34594561 | ||
| Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma | Q34664981 | ||
| Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo | Q35235365 | ||
| BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth | Q35251663 | ||
| Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells | Q35824223 | ||
| Immunology beats cancer: a blueprint for successful translation | Q36318789 | ||
| Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer | Q36352827 | ||
| Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody | Q36544926 | ||
| RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors | Q37048053 | ||
| Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than "Exhaustion" of Human CD8 T Cells | Q37402534 | ||
| PD-1 signaling in primary T cells | Q37474915 | ||
| ERK and cell death: ERK location and T cell selection | Q37618290 | ||
| Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma | Q37697778 | ||
| Mitigating the toxic effects of anticancer immunotherapy | Q38180319 | ||
| Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma | Q38241987 | ||
| Combination therapy of melanoma using kinase inhibitors | Q38324817 | ||
| Nivolumab: targeting PD-1 to bolster antitumor immunity | Q38387311 | ||
| Evolving synergistic combinations of targeted immunotherapies to combat cancer. | Q38553010 | ||
| Trametinib Drives T-cell-Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis | Q38734237 | ||
| MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade | Q38788877 | ||
| Reversing T-cell Dysfunction and Exhaustion in Cancer | Q38809776 | ||
| The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4. | Q38919859 | ||
| Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway | Q38996832 | ||
| Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. | Q38998443 | ||
| Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function | Q39692699 | ||
| The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations | Q39803993 | ||
| PD1 signal transduction pathways in T cells. | Q40062424 | ||
| Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. | Q40236161 | ||
| T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. | Q40248504 | ||
| Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation | Q40957673 | ||
| Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma | Q40987506 | ||
| TCR activation kinetics and feedback regulation in primary human T cells | Q42049006 | ||
| Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells | Q42233712 | ||
| Cell cycle arrest caused by MEK/ERK signaling is a mechanism for suppressing growth of antigen-hyperstimulated effector T cells | Q42728732 | ||
| T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. | Q44384732 | ||
| The diverse functions of the PD1 inhibitory pathway | Q47678849 | ||
| RAF inhibition and induction of cutaneous squamous cell carcinoma. | Q51770070 | ||
| Contribution of naïve and memory T-cell populations to the human alloimmune response. | Q51891672 | ||
| Inhibition of T cell activation by pharmacologic disruption of the MEK1/ERK MAP kinase or calcineurin signaling pathways results in differential modulation of cytokine production. | Q52529596 | ||
| T Cell Dysfunction in Cancer. | Q52596337 | ||
| Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370). | Q52666574 | ||
| A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy. | Q52689094 | ||
| Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response. | Q52874301 | ||
| MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells. | Q54357319 | ||
| Activation of human T cells with superantigen (staphylococcal enterotoxin B) and CD28 confers resistance to apoptosis via CD95 | Q56907832 | ||
| P433 | issue | 1 | |
| P304 | page(s) | e1512456 | |
| P577 | publication date | 2018-10-29 | |
| P1433 | published in | OncoImmunology | Q18026500 |
| P1476 | title | BRAF and MEK inhibitors differentially affect nivolumab-induced T cell activation by modulating the TCR and AKT signaling pathways | |
| P478 | volume | 8 |
| Q89673895 | Prebiotic-Induced Anti-tumor Immunity Attenuates Tumor Growth | cites work | P2860 |
Search more.